Warning Label Urged for Avandia

A FDA advisory panel on Monday found that people who use the popular diabetes pill Avandia face a greater risk of heart attack and urged the FDA to slap its strictest warning on its label.

Type 2 Diabetes Drug Avandia Should be Pulled, PC Testifies

Diabetes drug Avandia should be removed from the market, public citizen tells FDA advisory committee popular drug associated with risks to multiple organ systems has no benefit over older, safer type 2 diabetes drugs.

Diabetes Drug Avandia Should be Pulled from Market

The widely used diabetes drug Avandia should be pulled from the market because of heart risks, a federal scientist said Monday.

Restricted Use of Zelnorm for Qualifying Patients

The U.S. FDA announced that it is permitting the restricted use of Zelnorm under a treatment investigational new drug protocol to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in women younger than 55 who meet specific guidelines.

Warning for Women

For decades, Wyeth Pharmaceuticals marketed one of the nation's top selling drugs for relief. But now, there's a warning for women.

FDA Permits Restricted Use of Zelnorm for Qualifying Patients

The U.S. FDA announced that it is permitting the restricted use of Zelnorm (tegaserod maleate) under a treatment investigational new drug (IND) protocol to treat irritable bowel syndrome with constipation.

Zelnorm Back on the Market

The drug Zelnorm, manufactured by Novatis, was taken of the market in March because of a high risk of heart attacks, stroke, and chest pain.

The Fire Still Burns

In 1974, then-judge Miles Lord issued an environmental ruling that reverberated through the Iron Range taconite industry. Thirty-three years later, he's still fighting to protect its workers  and the health of all Minnesotans.

Avandia Warnings Might Have Prevented a Death

"My father started taking Avandia shortly after it was approved in 1999 but we didn't hear about the dangers of this drug until June of this year," says Pender.

Hearings May Wait on Govs' Testimony in Vioxx Case

Arguments on two questions in federal Vioxx cases may wait on testimony from two governors who have worked in or for the drug industry about consultations with the FDA about drug label rules made last year.